GLP-1 drugs show promise for heart failure with preserved ejection fraction in obese patients | Research

The takeaway

STEP-HFpEF and SUMMIT trials show semaglutide and tirzepatide reduce weight by 13-14%, improve 6-minute walk distance by 21-26m, and reduce CRP by 39-44% in obese patients with HFpEF.

13-14% weight loss + cardiac benefit
Semaglutide and tirzepatide improved heart failure symptoms, exercise capacity, and inflammation alongside major weight reduction

What the researchers found

In STEP-HFpEF and SUMMIT trials, semaglutide and tirzepatide achieved 13.3% and 13.9% weight reduction, 21.5m and 26m improvements in 6MWD, 19.5 and 16.6 point KCCQ-CSS improvements, and 38.8% and 43.5% CRP reductions in obese HFpEF patients.

Why it matters

HFpEF in obesity has limited treatment options and growing prevalence. GLP-1 drugs addressing both the cardiac symptoms and the underlying obesity represents a paradigm shift in managing this challenging condition.

The numbers in context

Semaglutide: 13.3% weight loss, +21.5m 6MWD, +19.5 KCCQ-CSS, -38.8% CRP. Tirzepatide: 13.9% weight loss, +26m 6MWD, +16.6 KCCQ-CSS, -43.5% CRP. From STEP-HFpEF and SUMMIT trials.

How the study worked

Narrative review synthesizing clinical trial data including STEP-HFpEF and SUMMIT studies on GLP-1RAs for HFpEF in obesity.

Who was studied

Obese patients with HFpEF

What this study cannot tell us

Short trial durations. Limited population diversity. No long-term hospitalization or mortality data yet. Benefits may be partly mediated by weight loss rather than direct cardiac effects.

How to read the evidence

Review of high-quality randomized trials (STEP-HFpEF, SUMMIT). Strong short-term evidence but lacks long-term outcome data.

When this study was published

Published in 2025; synthesizes the latest landmark trial data.

The bigger picture

HFpEF affects half of all heart failure patients and has been notoriously difficult to treat. These GLP-1 drugs are the first therapies to show meaningful benefit by targeting the metabolic root cause rather than just managing symptoms.

Questions still open

Do GLP-1 drugs reduce heart failure hospitalizations and mortality in HFpEF?
Are benefits maintained long-term or do they plateau?
Would non-obese HFpEF patients also benefit?

Common questions

Can GLP-1 drugs treat heart failure?

For a specific type—heart failure with preserved ejection fraction (HFpEF) in obese patients—clinical trials show GLP-1 drugs like semaglutide significantly improve symptoms, exercise ability, and quality of life while reducing weight and inflammation.

How much do these drugs improve heart failure symptoms?

Patients walked 21-26 meters farther in 6-minute walk tests, had 16-20 point improvements in quality of life scores (clinically meaningful), and showed 39-44% reductions in inflammation markers. Weight loss of 13-14% likely contributed to these improvements.

Read the original research

Therapeutic Potential of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction (HFpEF) in Obese Patients.

Current heart failure reports, 22(1), 17

View on PubMed ↗Publisher’s paper ↗

Citation

Patel, Ravi; Kokori, Emmanuel; Olatunji, Gbolahan; Adejumo, Faith Adedayo; Ukah, Joan Dumebi; Babalola, Adetola Emmanuel; Ndakotsu, Andrew; Abraham, Israel Charles; Aderinto, Nicholas. (2025). Therapeutic Potential of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction (HFpEF) in Obese Patients.. Current heart failure reports, 22(1), 17. https://doi.org/10.1007/s11897-025-00704-1